Ironwood, Allergan score data backing for smaller Linzess dose; Lupin signs up to market BI diabetes med in India;

> Ironwood Pharmaceuticals ($IRWD) said a smaller dose of the constipation drug Linzess was effective in a late-stage study; the company and partner Allergan ($AGN) plan to ask the FDA to approve the 72-mcg dose early next year. Report

> India's Lupin inked a deal to co-market Boehringer Ingelheim's diabetes drug Trajenta in its home country, under a different brand name, Ondero. Report

> Bristol-Myers Squibb's ($BMY) Ready. Raise. Rise. campaign recognized 23 cancer advocacy groups in an immuno-oncology awareness effort. Release

> GlaxoSmithKline ($GSK) is socking £1.3 million into a marketing push for a new toothpaste product, Sensodyne True White; the move follows an overall simplification of the Sensodyne product line. Report

> Pfizer ($PFE) snapped up full rights to the Gaucher's disease drug Elelyso from partner Protalix for $36 million cash, in a deal that also includes a $10 million investment in the smaller company. Report

And Finally... Pfizer's stop-smoking drug Chantix, equally effective in men and women after one year, was more helpful to women than men early on in therapy, according to a new study. Report

Suggested Articles

Pfizer terminated a slew of trial cohorts testing Bavencio in combination with its own experimental drugs, as well as one monotherapy trial.

NICE rejected Spravato over cost concerns and a lack of head-to-head clinical data against other NICE-recommended alternatives.

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?